Regadenoson + Placebo
ApprovedCompleted 0 watching 0 views this week🔥 Hot
85
Development Stage
✓
Pre-clinical✓
Phase 1✓
Phase 2✓
Phase 35
ApprovedIndication / Disease
Asthma
Conditions
Asthma, Coronary Artery Disease, Pulmonary Disease, Chronic Obstructive
Trial Timeline
Apr 1, 2009 → Oct 1, 2009
NCT ID
NCT00862641About Regadenoson + Placebo
Regadenoson + Placebo is a approved stage product being developed by Astellas Pharma for Asthma. The current trial status is completed. This product is registered under clinical trial identifier NCT00862641. Target conditions include Asthma, Coronary Artery Disease, Pulmonary Disease, Chronic Obstructive.
Hype Score Breakdown
Clinical
30
Activity
20
Company
10
Novelty
10
Community
12
Clinical Trials (3)
| NCT ID | Phase | Status |
|---|---|---|
| NCT01918995 | Phase 1 | Completed |
| NCT00862641 | Approved | Completed |
| NCT00863707 | Approved | Completed |
Competing Products
20 competing products in Asthma